A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages

  Filí, Lucia ^a   Vultaggio, Alessandra ^a   Cardilicchia, Elisa ^a   Manuelli, Cinzia ^a   Casini, Andrea ^b   Nencini, Francesca ^a   Maggi, Laura ^a   Pratesi, Sara ^a   Petroni, Giulia ^a   Boscaro, Francesca ^b   Guarna, Antonio ^b   Occhiato, Ernesto G ^b   Romagnani, Sergio ^a   Maggi, Enrico ^a   Parronchi, Paola ^a  

^a Transfer and High Education for the Development of De Novo Therapies (DENOTHE)   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adenine derivatives; Adjuvants; Allergy; Immunotherapy; Toll like receptors; Vaccines

Indexed keywords

4 (6 AMINO 9 BENZYL 8 HYDROXY 9 H ACID SUCCINIMIDYL ESTER; BUTYRIC ACID DERIVATIVE; DER P2; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; NDER P 2; SA 26E; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; CELL STIMULATION; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONJUGATION; CONTACT SENSITIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATOPHAGOIDES; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LYMPHOCYTE CLONE; MASS SPECTROMETRY; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT ALLERGY; TH1 CELL; TH17 CELL; UPREGULATION;

EID: 84882877056     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.01.030     Document Type: Article

References (45)

1. Romagnani S. T-cell responses in allergy and asthma. Curr Opin Allergy Clin Immunol 2001;1:73-8.
2. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11: 586-93.
3. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105: 17908-12.
4. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009;60: 279-91.
5. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012;30:4328-35.
6. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-9.
7. Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011; 366:2748-55.
8. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008;4:347-9.
9. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011;154:336-44.
10. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106:124-34.
11. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004;113:1144-51.
12. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113: 235-41.
13. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55.
14. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005;102:15190-4.
15. Kastenmuller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 2011;121:1782-96.
16. Fili L, Ferri S, Guarna F, Sampognaro S, Manuelli C, Liotta F, et al. Redirection of allergen-specific Th2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J Allergy Clin Immunol 2006;118: 511-7.
17. Vultaggio A, Nencini F, Fitch PM, Fili L, Maggi L, Fanti P, et al. Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 2009;182:880-9.
18. Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ Th2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003;111:380-8.
19. Leech MD, Benson RA, De Vries A, Fitch PM, Howie SE. Resolution of Der p 1-induced allergic airway inflammation is dependent on CD4+CD25+Foxp3+ regulatory cells. J Immunol 2007;179:7050-8.
20. Vultaggio A, Nencini F, Pratesi S, Maggi L, Guarna A, Annunziato F, et al. The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines. J Immunol 2011;186:4707-15.
21. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503.
22. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011;12:509-17.
23. Frew AJ. Hundred years of allergen immunotherapy. Clin Exp Allergy 2011;41: 1221-5.
24. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011;66:725-32.
25. Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2012;12:1-6.
26. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J Immunol 1999;163: 6448-54.
27. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008;38:2068-71.
28. Musmuca I, Simeoni S, Caroli A, Ragno R. Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches. J Chem Inf Model 2009;49:1777-86.
29. Trombone AP, Tobias KR, Ferriani VP, Schuurman J, Aalberse RC, Smith AM, et al. Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. Clin Exp Allergy 2002;32:1323-8.
30. Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 2011;41:1334-43.
31. Cosmi L, Annunziato F, Galli G, Maggi M, Nagata K, Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000;30:2972-9.
32. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168:554-61.
33. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda 1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009;113:5829-38.
34. Oh JZ, Kedl RM. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J Immunol 2010; 185:4602-8.
35. Brand S, Teich R, Dicke T, Harb H, Yildirim AÖ, Tost J, et al. Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by microbes. J Allergy Clin Immunol 2011;128:618-25.
36. Brand S, Kesper DA, Teich R, Kilic-Niebergall E, Pinkenburg O, Bothur E, et al. DNA methylation of T(h)1/T(h)2 cytokine genes affects sensitization and progress of experimental asthma. J Allergy Clin Immunol 2012;129:1602-10.
37. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy 2011;66:989-98.
38. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Tolllike receptor 7 engagement. J Exp Med 2005;202:1171-7.
39. Ewald SE, Barton GM. Nucleic acid sensing Toll-like receptors in autoimmunity. Curr Opin Immunol 2011;23:3-9.
40. Hirota K, Kazaoka K, Niimoto I, Sajiki H. Efficient synthesis of 2, 9-disubstituted 8-hydroxyadenine derivatives. Org Biomol Chem 2003;1:1354-65.
41. Kurimoto AT, Ogino S, Ichii Y, Isobe M, Tobe H, Ogita H, et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg Med Chem 2004;12:1091-9.
42. Fili L, Ferri S, Guarna F, Sampognaro S, Manuelli C, Liotta F, et al. Redirection of allergen-specific Th2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J Allergy Clin Immunol 2006;118:511-7.
43. Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ Th2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003;111:380-8.
44. Vultaggio A, Nencini F, Fitch PM, Fili L, Maggi L, Fanti P, et al. Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 2009;182:880-9.
45. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-28.